Diabetes. Non-insulin-dependent diabetes mellitus
Conditions
Interventions
Intervention 1: Intervention group: Received 2.5 ml N. sativa oil two times a day orally for three months. Intervention 2: Placebo group: Received 2.5 ml mineral oil orally two times a day for three m
Treatment - Drugs
Placebo
Intervention group: Received 2.5 ml N. sativa oil two times a day orally for three months
Placebo group: Received 2.5 ml mineral oil orally two times a day for three months
Sponsors
Vice chancellor for research, Institute of Medicinal Plants
Vice chancellor for research, Religion and Medicine Research Center, Baqiyatallah University of Medi
Eligibility
Sex/Gender
All
Age
34 Years to 63 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Type 2 diabetic patients with fasting blood glucose levels between 140 and 180 mg/dl; body weight between 55 and 75 kg; age between 34 and 63 years; disease duration of 2 to 8 years; taking no more than two 500 mg metformin and two 5 mg glyburide tablets every day. Exclusion criteria: Patients receiving insulin therapy; patients with cardiac, renal, hepatic and hematological diseases; patients with a history of gallstones or gall bladder surgery; patients using estrogen, steroid, beta-blocker and thiazide drugs; pregnant and breast-feeding women; alcohol consuming and cigarette smoking patients.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fasting blood glucose. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood glucose level was determined in laboratory by commercially available kit.;Glycosylated hemoglobin (HbA1C). Timepoint: At starting of the study and after 3 months. Method of measurement: Blood HbA1c level was determined in laboratory by commercially available kit.;2 hours postprandial blood glucose. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood glucose level was determined in laboratory by commercially available kit. | — |
Secondary
| Measure | Time frame |
|---|---|
| BMI (Body mass index). Timepoint: At starting of the study and after 3 months. Method of measurement: Height and weight using measure tape and weight scales.;Triglyceride. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood triglyceride level was determined in laboratory by commercially available kit.;Cholesterol. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood cholesterol level was determined in laboratory by commercially available kit.;Low-density lipoprotein (LDL). Timepoint: At starting of the study and after 3 months. Method of measurement: Blood LDL level was determined in laboratory by commercially available kit.;High-density lipoprotein (HDL). Timepoint: At starting of the study and after 3 months. Method of measurement: Blood HDL level was determined in laboratory by commercially available kit.;Serum glutamic oxaloacetic transaminase (SGOT). Timepoint: At starting of the study and after 3 months. Method of measurement: Blood SGOT level was determined in laboratory by commercially available kit.;Serum glutamic pyruvic transaminase (SGPT). Timepoint: At starting of the study and after 3 months. Method of measurement: Blood SGPT level was determined in laboratory by commercially available kit.;Creatinine. Timepoint: At starting of the study and after 3 months. Method of measurement: Blood creatinine level was determined in laboratory by commercially available kit.;Alkaline phosphatase (ALP). Timepoint: At starting of the study and after 3 months. Method of measurement: Blood ALP level was determined in laboratory by commercially available kit. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHasan Fallah Huseini
Institute of Medicinal Plants
Outcome results
None listed